Anbio Biotechnology Stock Rises Following Analyst Upgrade to Hold Rating

Anbio Biotechnology (NASDAQ:NNNN) shares rose during recent trading sessions, with the stock gaining 8.6% on Friday to close at $29.92 and 10% on Wednesday to close at $25.85. The stock traded as high as $30.49 on Friday and $26.17 on Wednesday.

The rating agency upgraded shares of Anbio Biotechnology from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Monday, February 9th. One research analyst has rated the stock with a Hold rating, and the stock currently has a consensus rating of "Hold".

Trading volume showed approximately 24,754 shares traded hands during mid-day trading on Friday, a decline of 62% from the average daily volume of 64,592 shares. On Wednesday, approximately 7,355 shares were traded during trading, a decline of 89% from the average daily volume of 68,845 shares.

The company last announced its quarterly earnings data on Tuesday, December 30th. The company reported $0.04 earnings per share for the quarter. The company had revenue of $2.29 million during the quarter.

Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. The company's extensive portfolio comprises an array of IVD products designed to cater to diverse diagnostic needs. The company's comprehensive range encompasses solutions for various applications, including over-the-counter (OTC) utilization, point-of-care (POCT) settings, and laboratory applications.

The company's IVD products are designed to detect a wide range of biomarkers associated with critical medical domains. These domains encompass infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. The IVD products are compatible with multiple sample collection matrices, including serum, plasma, whole blood, feces, urine, and saliva.

The company's main sales revenue was from SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B Antigen Rapid Test Kit, under its Lateral Flow Immunoassay (LFIA) technology, which accounted for over 60% and 99% of total revenue for the fiscal year ended December 31, 2023 and 2022, respectively, and 44% and 99% of total revenue for the six months ended June 30, 2024 and 2023, respectively.

For the six months ended June 30, 2024 and 2023, the company generated revenue of $5.85 million and $3.06 million, respectively, of which 44% and 99% were from respiratory diseases and COVID-19 related products. For the six months ended June 30, 2024 and 2023, 63% and 99% of revenue were generated in the European Union.

For the fiscal years ended December 31, 2023 and 2022, the company generated revenue of $6.71 million and $23.54 million, respectively, of which 60% and 99% were from respiratory diseases and COVID-19 related products.

In a comparison with Oncocyte (NASDAQ:IMDX), Anbio Biotechnology has higher revenue and earnings. Anbio Biotechnology reported gross revenue of $8.19 million with a price/sales ratio of 452.58 and net income of $2.37 million, while Oncocyte reported gross revenue of $1.88 million with a price/sales ratio of 91.62 and net income of -$60.66 million. 55.4% of Oncocyte shares are owned by institutional investors, while 2.1% of Oncocyte shares are owned by company insiders.